Teva seeks to add more patents to US suit against Momenta/Sandoz on Copaxone
11 November 2009
Nancy Faigen
Teva Pharmaceutical Industries is seeking to expand an existing lawsuit against
Momenta Pharmaceuticals and
Sandoz (Novartis) as it relates to their effort to market a generic version of Teva's blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) in the US. Teva now says that the firms...
Please Login to read the full article.
11 November 2009
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
NEWS
- Teva in US agrees to 2017 for Vytorin generic, as Merck has other pending cases
- Sanofi loses again, as US judge upholds FDA's different generic 'sameness' criteria
- US FDA denies Teva's plea to reject generic Copaxone apps
- Indian firms lead para IV charge, lock in key first-to-file opportunities
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
